NYSE:MRX Medicis Pharmaceutical (MRX) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$22.87▼$23.3550-Day Range N/A52-Week Range N/AVolume230,024 shsAverage Volume120,042 shsMarket Capitalization$1.64 billionP/E RatioN/ADividend YieldN/APrice Target$26.71 Stock AnalysisStock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesOptions ChainTrendsStock AnalysisAnalyst ForecastsCompetitorsDividendEarningsHeadlinesOptions ChainTrends Get Medicis Pharmaceutical alerts: Email Address Medicis Pharmaceutical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside15.5% Upside$26.71 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth15.28%From $2.29 to $2.64 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.66 out of 5 starsFinance Sector816th out of 863 stocksSecurity & Commodity Brokers, Dealers, Exchanges & Services Industry11th out of 11 stocks 2.5 Analyst's Opinion Consensus RatingMedicis Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMedicis Pharmaceutical has only been the subject of 2 research reports in the past 90 days.Read more about Medicis Pharmaceutical's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MRX. Previous Next 0.0 Dividend Strength Dividend YieldMedicis Pharmaceutical does not currently pay a dividend.Dividend GrowthMedicis Pharmaceutical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Medicis Pharmaceutical this week, compared to 0 articles on an average week.Search Interest2 people have searched for MRX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Medicis Pharmaceutical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.79% of the stock of Medicis Pharmaceutical is held by insiders.Read more about Medicis Pharmaceutical's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Medicis Pharmaceutical are expected to grow by 15.28% in the coming year, from $2.29 to $2.64 per share.Read more about Medicis Pharmaceutical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. About Medicis Pharmaceutical Stock (NYSE:MRX)Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries is an independent specialty pharmaceutical company engaged in the development and marketing of products for the treatment of dermatological and aesthetic conditions in the United States and Canada. Medicis offers a range of products addressing various conditions or aesthetic improvements, including facial wrinkles. Its brands are DYSPORT (abobotulinumtoxinA) 300 Units for Injection, PERLANE Injectable Gel, RESTYLANE Injectable Gel, SOLODYN (minocycline HCl, USP) Extended Release Tablets, VANOS (fluocinonide) Cream 0.1%, ZIANA (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel and ZYCLARA (imiquimod) Cream 3.75% and 2.5%. As of December 31, 2011, it offered 27 branded products. On December 2, 2011, it acquired Graceway Pharmaceuticals, LLC (Graceway). On November 1, 2011, Medicis sold Medicis Technologies Corporation, formerly LipoSonix, Inc., to Solta Medical, Inc. (Solta).Read More Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. MRX Stock News HeadlinesAugust 16, 2024 | fool.comWhy Marex Group Stock Was Skyrocketing This WeekAugust 14, 2024 | globenewswire.comMarex Group plc announces 2024 Interim ResultsAugust 22, 2024 | Angel Publishing (Ad)What Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.July 19, 2024 | globenewswire.comMarex Group plc Provides Notice of H1 2024 Results and Conference CallJuly 16, 2024 | globenewswire.comMarex Opens New Zealand OfficeJune 18, 2024 | globenewswire.comMarex Appoints Liz Barrett as Group Head of HRJune 17, 2024 | globenewswire.comMarex to offer client clearing of interest rate swapsMay 31, 2024 | globenewswire.comMarex Group plc to Participate in Upcoming Piper Sandler Global Exchange & FinTech ConferenceAugust 22, 2024 | Angel Publishing (Ad)What Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment for as much as $7,882 — each quarter.May 29, 2024 | investorplace.comWall Street's New Favorites: 3 Stocks Analysts Are Raving About in MayMay 16, 2024 | globenewswire.comMarex Group plc Announces Full Year 2023 Results and Q1 2024 UpdateMay 15, 2024 | bbc.co.ukThe MediciMay 13, 2024 | globenewswire.comMarex Group plc to Report FY 2023 Results and Q1 2024 Update on May 16, 2024May 10, 2024 | morningstar.comMister Spex SE MRXApril 29, 2024 | investorplace.comWhy Is Marex (MRX) Stock On the Move Today?April 25, 2024 | finance.yahoo.comIPOs Shine Bright in a Tough Day for StocksApril 24, 2024 | reuters.comBritish commodities platform Marex prices US IPO at $1.35 bln valuationApril 24, 2024 | globenewswire.comMarex Group plc Announces Pricing of Initial Public OfferingSee More Headlines Receive MRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medicis Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today8/21/2024Ex-Dividend for 9/16 Dividend8/30/2024Dividend Payable9/16/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorFinance Industry Security & commodity brokers, dealers, exchanges & services Sub-IndustryN/A Current SymbolNYSE:MRX CUSIPN/A CIK859368 Webwww.Medicis.com Phone+1-212-5992000FaxN/AEmployees2,074Year FoundedN/APrice Target and Rating Average Stock Price Target$26.71 High Stock Price Target$33.00 Low Stock Price Target$24.00 Potential Upside/Downside+15.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares70,820,000Free Float68,134,000Market Cap$1.64 billion OptionableOptionable BetaN/A 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesRobert Roswell Chai-Onn (Age 44)Executive Vice President, General Counsel, Secretary, Director Howard Bradley Schiller (Age 53)Officer, Director Ryan WeldonOfficer, DirectorKey CompetitorsBGC GroupNASDAQ:BGCStoneX GroupNASDAQ:SNEXForge GlobalNYSE:FRGEGarden StageNASDAQ:GSIWTOP Financial GroupNASDAQ:TOPView All Competitors MRX Stock Analysis - Frequently Asked Questions How were Medicis Pharmaceutical's earnings last quarter? Medicis Pharmaceutical Corp (NYSE:MRX) issued its earnings results on Wednesday, August, 14th. The healthcare company reported $0.90 earnings per share for the quarter, topping analysts' consensus estimates of $0.53 by $0.37. The company's revenue was up 15.4% compared to the same quarter last year. When did Medicis Pharmaceutical IPO? Medicis Pharmaceutical (MRX) raised $292 million in an initial public offering (IPO) on Thursday, April 25th 2024. The company issued 15,384,615 shares at $19.00 per share. When does the company's lock-up period expire? Medicis Pharmaceutical's lock-up period expires on Tuesday, October 22nd. Medicis Pharmaceutical had issued 15,384,615 shares in its IPO on April 25th. The total size of the offering was $292,307,685 based on an initial share price of $19.00. After the end of the company's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted. This page (NYSE:MRX) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | SponsoredYou’ve been lied to for 615 days, and countingAll of the hype around artificial intelligence has been nothing but an artificial illusion…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicis Pharmaceutical Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicis Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MRX Stock Alerts